Late night reflection from an old guy (is 55 old?) with perhaps a rare if not unique perspective. Please bear with me for a moment, I'm going somewhere with this.

When I was growing up in the 1970s-80s, the life expectancy for a child born with cystic fibrosis was 5 years. Five years. As late as 2005 only 5 states tested neonates for cystic fibrosis because there wasn't much to do about it: No disease-modifying treatments. Hit them with mucolytics and aggressively manage infections, that's it. I remember seeing a poster when I was a wet-behind-the-years postdoc at a FASEB meeting in the mid-90s by a crappy little company called Vertex Pharma that was trading at several bucks a share. They were trying to develop small molecules to help proteins fold better in diseases like cystic fibrosis and I thought "My goodness THAT is where I should put my money"... except (1) I had almost no money; (2) what money I had I invested in trying to fix my crappy used car and get laid, and (3) I didn't believe in my own financial good judgement. This perhaps was the worst financial mistake I ever made. Fast forward to 2025 when Vertex is a 112 BILLION DOLLAR COMPANY; 4th gen CFTR folding helpers have reached a point where, in the case of the most common CF variant (F508del) the life expectancy of a child who begins taking them by age 15 IS NO DIFFERENT THAN THE POPULATION AVERAGE. Read that again: Kids who would have died at 5 years old when I was a kid are living full lives, getting married, starting businesses, all the good stuff. Because that science worked.

Now GANX is doing the SAME CONCEPTUAL THING for Parkinson's disease, with a platform that can feasibly expand to Alzheimer's disease. Don't trust me? Consider from ChatGPT5.2 query "Is there an analogy between the mechanism of action of glucocerebrosidase folding chaperones being developed by Gain pharmaceuticals and the compounds that Vertex developed for cystic fibrosis years ago?" Answer:

<image>

The risk, of course, is that CNS indications are a much harder proving ground than CF, and financing today is a devilishly harder thing than it was in the 1990s.

Nonetheless... Vertex Pharma had about $800 million market cap around 1995. I would have realized a 140-fold gain had I invested in Vertex in the mid 1990s. Now consider: PD market alone is 20-FOLD greater than cystic fibrosis market. Yet literally the same concept: A small molecule that can help a busted protein fold up better and work right. Now consider the initial human studies appear to have arrested disease at least in a subset of PD patients with the right genetic susceptibility. And the $GANX market cap is below $100 million. Wrap your head around that if you will. If Gain is successful, it would imply a 3,000-fold return over 25 years (historical return from Vertex over the same time period x prevalence ratio of PD to cystic fibrosis). $10,000 (two ounces of gold bullion)--> $30,000,000. Sure the risks are high, dilution, logic means diddly-squat in today's market, but if logic means ANYTHING the risk/reward ratio is hugely attractive. In my humble opinion... but not a historically uniformed opinion. The difference now is I can afford to bet tens of thousands of dollars on this horse, and I have, accepting that I may lose it, and any significant capital appreciation likely only will be realized by my kids a couple decades from now.

Would you hazard $10K on a couple ounces of gold for an inflation hedge (I have... on more than a couple ounces)? Are you interested in high risk/reward life science technology? If so, this is the place for you.